Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells
Identifieur interne : 001B57 ( Main/Exploration ); précédent : 001B56; suivant : 001B58Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells
Auteurs : Haiming Xu [États-Unis] ; Donghong Ju [États-Unis] ; Tiffany Jarois [États-Unis] ; Youming Xie [États-Unis]Source :
- Breast Cancer Research and Treatment [ 0167-6806 ] ; 2008-01-01.
English descriptors
Abstract
Abstract: Clinical trials with proteasome inhibitor Bortezomib (also named Velcade or PS-341) has shown promising results for some cancers. However, other types of cancers including breast cancer do not respond well to Bortezomib. To understand the cause of the drug resistance, we compared the regulation of proteasome expression and the sensitivity to proteasome inhibitors between human breast cancer cells and nontumorigenic mammary epithelial cells. We found that, while the endogenous expression level is much higher, the potential of feedback expression in response to proteasome inhibitors is much lower in the breast cancer cells. Furthermore, the breast cancer cells are much more resistant to proteasome inhibitors compared to the nontumorigenic mammary epithelial cells. Biochemical analysis showed that the pathway of Bortezomib-induced apoptosis is apparently defective in the breast cancer cells. Together, these results provide an explanation for the inefficacy of Bortezomib in the clinical trials for breast cancer patients. The likelihood of combination therapy with Bortezomib and other anti-cancer agents for breast cancer is also discussed.
Url:
DOI: 10.1007/s10549-007-9553-4
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001724
- to stream Istex, to step Curation: 001724
- to stream Istex, to step Checkpoint: 000A40
- to stream Main, to step Merge: 001B68
- to stream Main, to step Curation: 001B57
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells</title><author><name sortKey="Xu, Haiming" sort="Xu, Haiming" uniqKey="Xu H" first="Haiming" last="Xu">Haiming Xu</name></author><author><name sortKey="Ju, Donghong" sort="Ju, Donghong" uniqKey="Ju D" first="Donghong" last="Ju">Donghong Ju</name></author><author><name sortKey="Jarois, Tiffany" sort="Jarois, Tiffany" uniqKey="Jarois T" first="Tiffany" last="Jarois">Tiffany Jarois</name></author><author><name sortKey="Xie, Youming" sort="Xie, Youming" uniqKey="Xie Y" first="Youming" last="Xie">Youming Xie</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C598F9AEF1974C3D767472815B161D219D23ABB6</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1007/s10549-007-9553-4</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-88QLLSK2-W/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001724</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001724</idno><idno type="wicri:Area/Istex/Curation">001724</idno><idno type="wicri:Area/Istex/Checkpoint">000A40</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000A40</idno><idno type="wicri:doubleKey">0167-6806:2007:Xu H:diminished:feedback:regulation</idno><idno type="wicri:Area/Main/Merge">001B68</idno><idno type="wicri:Area/Main/Curation">001B57</idno><idno type="wicri:Area/Main/Exploration">001B57</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells</title><author><name sortKey="Xu, Haiming" sort="Xu, Haiming" uniqKey="Xu H" first="Haiming" last="Xu">Haiming Xu</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Barbara Ann Karmanos Cancer Institute, Department of Pathology, Wayne State University School of Medicine, 110 E Warren Ave, 48201, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Ju, Donghong" sort="Ju, Donghong" uniqKey="Ju D" first="Donghong" last="Ju">Donghong Ju</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Barbara Ann Karmanos Cancer Institute, Department of Pathology, Wayne State University School of Medicine, 110 E Warren Ave, 48201, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Jarois, Tiffany" sort="Jarois, Tiffany" uniqKey="Jarois T" first="Tiffany" last="Jarois">Tiffany Jarois</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Biological Sciences, Wayne State University, 1360 BioScience Bldg, 48202, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Xie, Youming" sort="Xie, Youming" uniqKey="Xie Y" first="Youming" last="Xie">Youming Xie</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Barbara Ann Karmanos Cancer Institute, Department of Pathology, Wayne State University School of Medicine, 110 E Warren Ave, 48201, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Breast Cancer Research and Treatment</title><title level="j" type="abbrev">Breast Cancer Res Treat</title><idno type="ISSN">0167-6806</idno><idno type="eISSN">1573-7217</idno><imprint><publisher>Springer US; http://www.springer-ny.com</publisher><pubPlace>Boston</pubPlace><date type="published" when="2008-01-01">2008-01-01</date><biblScope unit="volume">107</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="267">267</biblScope><biblScope unit="page" to="274">274</biblScope></imprint><idno type="ISSN">0167-6806</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0167-6806</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Breast cancer</term><term>Drug resistance</term><term>Feedback regulation</term><term>Proteasome</term><term>Proteasome inhibitor</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Clinical trials with proteasome inhibitor Bortezomib (also named Velcade or PS-341) has shown promising results for some cancers. However, other types of cancers including breast cancer do not respond well to Bortezomib. To understand the cause of the drug resistance, we compared the regulation of proteasome expression and the sensitivity to proteasome inhibitors between human breast cancer cells and nontumorigenic mammary epithelial cells. We found that, while the endogenous expression level is much higher, the potential of feedback expression in response to proteasome inhibitors is much lower in the breast cancer cells. Furthermore, the breast cancer cells are much more resistant to proteasome inhibitors compared to the nontumorigenic mammary epithelial cells. Biochemical analysis showed that the pathway of Bortezomib-induced apoptosis is apparently defective in the breast cancer cells. Together, these results provide an explanation for the inefficacy of Bortezomib in the clinical trials for breast cancer patients. The likelihood of combination therapy with Bortezomib and other anti-cancer agents for breast cancer is also discussed.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Michigan</li></region></list><tree><country name="États-Unis"><region name="Michigan"><name sortKey="Xu, Haiming" sort="Xu, Haiming" uniqKey="Xu H" first="Haiming" last="Xu">Haiming Xu</name></region><name sortKey="Jarois, Tiffany" sort="Jarois, Tiffany" uniqKey="Jarois T" first="Tiffany" last="Jarois">Tiffany Jarois</name><name sortKey="Ju, Donghong" sort="Ju, Donghong" uniqKey="Ju D" first="Donghong" last="Ju">Donghong Ju</name><name sortKey="Xie, Youming" sort="Xie, Youming" uniqKey="Xie Y" first="Youming" last="Xie">Youming Xie</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B57 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B57 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:C598F9AEF1974C3D767472815B161D219D23ABB6
|texte= Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells
}}
| This area was generated with Dilib version V0.6.33. |  |